CoreCap Advisors
BBNX icon

CoreCap Advisors’s Beta Bionics BBNX Stock Holding History

CoreCap Advisors’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20.8K Hold
1,095
– – ﹤0.01% 1768
2026
Q2 		$17.2K Sell
1,095
-394
-26% -$4.69K ﹤0.01% 1868
2026
Q1 		$14.9K Buy
1,489
+1,108
+291% +$16.4K ﹤0.01% 1787
2025
Q4 		$11.6K Sell
381
-100
-21% -$2.67K ﹤0.01% 1909
2025
Q3 		$9.6K Sell
481
-388
-45% -$6.82K ﹤0.01% 1955
2025
Q2 		$12.7K Buy
869
+309
+55% +$4.37K ﹤0.01% 1779
2025
Q1 		$6.85K Buy
+560
New +$10.4K ﹤0.01% 1979

Other funds holding BBNX

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Values First Advisors
Values First Advisors Gray, Tennessee $213M AUM 20.51% 1-Year Est. Return
Evanson Financial
Evanson Financial Mclean, Virginia $2.03B AUM
Iams Wealth Management
Iams Wealth Management Omaha, Nebraska $342M AUM 13.91% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Adirondack Trust Company
Adirondack Trust Company Saratoga Springs, New York $320M AUM 23.25% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

CoreCap Advisors's BBNX Position: Q3 2026 in Review

CoreCap Advisors held its Beta Bionics (BBNX) position steady in Q3 2026 at 1,095 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1768.

CoreCap Advisors first reported a position in BBNX in Q1 2025 and has held it in 7 quarters since. 18 funds tracked by Wall St. Rank hold BBNX as of Q3 2026.

  • CoreCap Advisors held 1,095 shares of Beta Bionics worth $20.8K as of Q3 2026.
  • CoreCap Advisors left its Beta Bionics share count unchanged in Q3 2026.
  • Beta Bionics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1768 holding.
  • CoreCap Advisors first reported a position in Beta Bionics in Q1 2025 and has held it in 7 quarters since.
  • 18 funds tracked by Wall St. Rank held Beta Bionics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.